• Pepstatin A in Protease and Macrophage Research

  2026-09-08

  Pepstatin A is an aspartic protease inhibitor with established utility in viral protein processing, HIV replication inhibition, and cathepsin research. This article connects its assay strengths to emerging macrophage infection models while clearly separating evidence from hypothesis.

• (S)-(+)-Methoprene Workflow for JH Studies

  2026-09-08

  Build cleaner assays for juvenile hormone signaling, developmental timing, and arthropod endocrine disruption with a defined juvenile hormone analog. This guide connects receptor activation to the miRNA–mRNA control of hormone biosynthesis and provides practical dosing, controls, and troubleshooting strategies.

• Bleomycin Sulfate in Fibrosis Assay Design

  2026-09-07

  Bleomycin Sulfate is more than a DNA damage reagent: it can anchor a staged workflow linking injury induction to macrophage-targeted fibrosis interventions. This article explains how to design, interpret, and translate such assays using mechanistic and delivery-focused evidence.

• Extra-Helical Binding of the GCGR Antagonist MK 0893

  2026-09-07

  The reference study solved a 2.5 Å structure of human glucagon receptor bound to MK 0893, revealing an unexpected allosteric pocket outside the seven-transmembrane bundle. This finding explains how the antagonist may block receptor activation and provides a structural framework for glucagon receptor antagonist discovery in type 2 diabetes research.

• MK-571 (L-660,711) Assay Guide

  2026-09-05

  This scenario-based guide explains how MK-571 (L-660,711), SKU B7023, can be used thoughtfully in leukotriene, viability, cytotoxicity, and MRP1-related experiments. It connects formulation control, assay design, and interpretation of macrophage protection data to practical laboratory decisions.

• Okadaic acid: PP1/PP2A Workflow Guide

  2026-09-04

  Okadaic acid (SKU A4540) provides concentration-dependent PP2A and PP1 inhibition for biochemical phosphatase assays and phosphorylation-linked cell studies. This guide covers handling, controls, and interpretation for apoptosis assay workflows; biochemical IC50 values are not universal cellular doses, and use is inappropriate when phosphatase selectivity or solvent exposure cannot be controlled.

• Preserving Phosphorylation in Proteostasis Research

  2026-09-04

  A translational perspective on how phosphatase control strengthens SIRT6, proteostasis, and neurodegeneration workflows.

• GM 6001: From MMP Inhibition to PNN Biology

  2026-09-03

  GM 6001 (Galardin) offers a powerful way to interrogate MMP-dependent extracellular matrix remodeling. This article connects its broad-spectrum activity to perineuronal-net biology, Alzheimer’s disease models, and better causal assay design.

• Tubeimoside I: ATP1A1-Targeted Senolysis in Aging

  2026-09-03

  A 2026 Phytomedicine study identifies tubeimoside I as a senolytic that preferentially eliminates senescent cells by targeting ATP1A1 and disrupting potassium-dependent ion homeostasis. Its combined in vitro and mouse-model evidence links ATP1A1 modulation to mitochondrial apoptosis, reduced senescence markers, and improved aging-associated outcomes, while also highlighting the need for orthogonal validation beyond metabolic viability assays.

• Mechanical Stress, Autophagy, and the Cytoskeleton

  2026-09-02

  The reference study provides direct evidence that compressive mechanical stress induces autophagy through a cytoskeleton-dependent process, with microfilaments serving as the principal structural component and microtubules making a supporting contribution. Its combination of cytoskeletal polymerization perturbation, fluorescence imaging, and western blotting offers a practical framework for studying how physical forces are converted into autophagic responses.

• Fludarabine: From DNA Synthesis to Assay Design

  2026-09-02

  Explore how Fludarabine, a DNA synthesis inhibitor, connects purine-analog biochemistry with rigorous oncology assay design. This guide adds a genotype-aware interpretation framework inspired by Waldenström macroglobulinemia therapy-sequencing research.

• Lanabecestat (AZD3293): Smarter BACE1 Assays

  2026-09-01

  Explore how Lanabecestat (AZD3293) supports mechanistically informed BACE1 assays, from amyloid-beta production inhibition to functional neuronal readouts. This article translates key findings from Satir et al. into practical experimental design and interpretation guidance.

• Propidium Iodide Workflows for Granulosa Cell Assays

  2026-09-01

  Propidium iodide converts membrane damage and DNA content into measurable fluorescence, making it a practical complement to CCK-8, Western blotting, and Annexin V in granulosa-cell research. This workflow translates AMH–SMAD4 findings in PCOS rats into actionable viability, apoptosis, and cell-cycle experiments.

• MK 0893: Glucagon Receptor Antagonist Workflows

  2026-08-31

  Build more interpretable GCGR binding and cAMP assays with MK 0893, a potent competitive reversible antagonist suited to receptor pharmacology and glucose-regulation studies. The workflow connects nanomolar cellular activity with practical solvent handling, selectivity controls, and translational testing in hGCGR animal models.

• Mitomycin C: From DNA Damage to Immune-Ready Models

  2026-08-31

  Mitomycin C is more than a conventional cytotoxic benchmark. As an antitumor antibiotic that forms covalent DNA adducts, it gives translational researchers a controllable way to study DNA replication inhibition, apoptosis priming, and TRAIL sensitization. This article connects those established applications with a recent HCC immunotherapy study while clearly separating validated evidence from hypothesis-generating opportunities.

8526 records 1/569 page Next 12345 下5页 Last page